US 2013/0156721 A1 · CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY

Abstract

The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.

Claims30

Dependent claims

A pharmaceutical composition comprising a sugar and a water soluble linear polymer conjugate, wherein the water soluble linear polymer conjugate comprises:

a linear polymer comprising cyclodextrin moieties and comonomers which do not contain cyclodextrin moieties (comonomers);
and
therapeutic agents covalently linked to the linear polymer, wherein the therapeutic agents are cleaved from the water soluble linear polymer conjugate under biological conditions to release the therapeutic agents;
wherein the water soluble linear polymer conjugate comprises at least four cyclodextrin moieties and at least four comonomers.

1 more element

Dependencies are inferred from the claim text.

Facts

Application

13/769,076Filed 15 Feb 2013

Priority

6 Sep 2002

Published

20 Jun 2013

Term ends

Not estimatedThe source records don’t support an estimate.

Classification32 codes

A61K 31/337
Having oxygen as the only ring hetero atom, e.g. fungichromin: having four-membered rings, e.g. taxol
A61K 31/7048
Compounds having saccharide radicals and heterocyclic rings: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin,…
A61K 47/58
The modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule: obtained by reactions only…
A61K 47/59
The modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule: obtained otherwise than by…

Family

Application60/408,855Us provisional application · filed 6 Sep 2002

Application60/422,830Us provisional application · filed 31 Oct 2002

Application60/451,998Us provisional application · filed 4 Mar 2003

Application10/656,838Continuation · filed 5 Sep 2003

Application11/881,325Division · filed 25 Jul 2007

Application13/277,780Continuation · filed 20 Oct 2011

Application13/572,283Continuation · filed 10 Aug 2012

Application13/769,076Continuation

Application13/277,780Division

Application11/881,325Continuation

US 2004/0077595 A1Published application